1.08
0.15 (16.13%)
| Penutupan Terdahulu | 0.930 |
| Jumlah Dagangan | 26,865,927 |
| Harga / Pendapatan (P/E Ke hadapan) | 46.87 |
| Harga / Jualan (P/S) | 3.06 |
| Harga / Buku (P/B) | 2.75 |
| Julat 52 Minggu |
| Margin Keuntungan | -119.54% |
| Margin Operasi (TTM) | -42.18% |
| EPS Cair (TTM) | -0.210 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 12,927.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 45.40% |
| Nisbah Semasa (MRQ) | 7.86 |
| Aliran Tunai Operasi (OCF TTM) | -204.34 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -142.38 M |
| Pulangan Atas Aset (ROA TTM) | -16.07% |
| Pulangan Atas Ekuiti (ROE TTM) | -45.35% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Geron Corporation | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -2.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | -0.3 |
| Persekitaran Makro | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | -0.81 |
|
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.09% |
| % Dimiliki oleh Institusi | 81.26% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Clearbridge Investments, Llc | 30 Jun 2026 | 19,648,853 |
| Eversept Partners, Lp | 30 Jun 2026 | 18,717,422 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |